Join us for an extraordinary evening of inspiration at the intersection of
art, science & technology

In Conversation with President

In Conversation with President


Thursday, September 22, 2022
Brooklyn, New York



The Next Frontiers of Science

George D. Yancopoulos, MD, PhD

George Damis Yancopoulos is Co-Founder, President, and Chief Scientist of Regeneron, as well as one of the most successful drug discoverers in biotech history. He is a principal inventor of blockbusters such as Eylea® and Dupixent®, which have collectively helped millions fight blindness and diseases like asthma and atopic dermatitis. Dr. Yancopoulos and his team also invented multiple industry-leading technologies—such as the VelocImmune® mouse (with a genetically humanized immune system that can efficiently generate human antibody drug candidates)—which have delivered additional important medicines such as Praluent® (first treatment targeting PCSK9 to lower LDL and heart disease), Libtayo® (leading treatment for non-melanoma skin cancers), and the first “antibody cocktail” treatments for Ebola and COVID-19, as well as one of biotech’s most innovative pipelines targeting diseases from cancer to allergy. Dr. Yancopoulos is a first-generation Greek-American who grew up in NYC, attending public schools and graduating as valedictorian of both the Bronx High School of Science and Columbia University, where he received his M.D. and Ph.D. in Biochemistry and Molecular Biophysics.

Ron Cohen, MD


Moderator Ron Cohen, MD, President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously, he was a principal in the start-up and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen is Chair of the Biotechnology Innovation Organization (BIO), and serves on the Board of Directors of VBL Therapeutics. He previously served as Director and Chair of the New York Biotechnology Association (NYBA). Dr. Cohen also serves as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service.

NextMed: What's Now, Near and Next in Health and Biomedicine

Daniel Kraft, MD

Daniel Kraft is a Stanford and Harvard-trained physician-scientist, inventor, and innovator and is serving as the Chair of the XPRIZE Pandemic & Health Alliance. With over 25 years of experience in clinical practice, biomedical research, and healthcare innovation, Kraft has served as faculty chair for Medicine at Singularity University since its inception and is founder and chair of NextMed Health (formerly Exponential Medicine), a program that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare. He recently launched Digital.Health and Continuum Health Ventures to accelerate the democratization of technology and healthcare. He is an Aspen Institute Health Innovation fellow and served for 14 years as a flight surgeon in the Air National Guard.

Rick A. Bright, PhD

Rick A. Bright was leading the development of a pandemic data-to-action platform that integrates modern technology, data analytics and global partners to help the world detect, prevent, and mitigate pandemic threats to achieve containment as quickly as possible. Prior to this role, he served as the Deputy Assistant Secretary for Preparedness and Response and the Director of the Biomedical Advanced Research and Development Authority (BARDA), in the U.S. Department of Health and Human Services. He also spent a decade in vaccine, therapeutics, and diagnostics development at the Centers for Disease Control and Prevention.

Shawna Butler, RN, MBA

Shawna is a nurse economist, managing director for NextMed, and the creator and host of SEE YOU NOW, a storytelling podcast produced in partnership with Johnson & Johnson and the American Nurses Association featuring human-centered, nurse-driven solutions addressing our most challenging healthcare problems. Her career centers on raising the visibility of nurses, empowering them as system-level change agents, and recognizing how they drive clinical and economic value and achieve health equity. She initiated a global conversation highlighting the rarity of nurses in boardrooms, product design, innovation teams, policy development, tech conferences, and health media. She's on a mission to change that! In 2021, she was honored by Rock Health as a Top 50 in Digital Health.

A Conversation on Heath Equity

Aletha Maybank, MD, MPH

Aletha Maybank, MD, MPH currently serves as the Chief Health Equity Officer and Senior Vice President for the American Medical Association (AMA) where she focuses on embedding health equity across all the work of the AMA and leading the Center for Health Equity. She joined the AMA in April 2019 as their inaugural Chief Health Equity Officer. Dr. Maybank previously served as Founding Director for the Center for Health Equity at the NYC Department of Health and Mental Hygiene (2014) and the Office of Minority Health in the Suffolk County Department of Health Services (2006). She is a nationally recognized speaker, writer, and advisor on issues related to health equity, the future of medicine, and public health impact.

Lori Grant


Lori Grant is CEO of Klick Health, overseeing the large independent health agency’s exponential growth (including global expansion overseas) and ongoing success.

As a highly regarded industry thought leader, Lori has been recognized as Med Ad News’ 2021 Industry Person of the Year, a PharmaVOICE 100 Most Inspiring People in Health, a MM+M inaugural "Hall of Femme" recipient, a PM360 ELITE Mentor, and a WXN Top 100 Most Powerful Women in Canada. She also sits on the Google Health Advisory Board, Canada’s Most Admired Corporate Cultures’ Board of Governors, and the Digital Health Coalition Advisory Board.

Personalizing Blockbuster Medicines

We are inching toward an individualized medical future in which the right patient takes the right drug at the right time in the right way, resulting in the right outcome. But we are far from delivering on this vision.

Roger Longman


Roger Longman is co-founder and chairman of Real Endpoints LLC, a leading reimbursement-focused analytics and advisory firm.

Roger is recognized as an expert in biopharmaceutical strategy and reimbursement and often speaks at key industry events organized by important trade organizations, investment banks, venture capital firms, and leading biopharma companies.

Michelle Carnahan

Michelle Carnahan is President of Thirty Madison, the premier healthcare company for people living with chronic conditions. After spending more than 25 years in healthcare and treatment innovation, Michelle joined Thirty Madison because of her commitment to patients and her desire to improve chronic care. As President, Michelle focuses on leading the company into the future, expanding its offerings, and ensuring a constant patient focus. Her background in strategy, marketing, and operations at Sanofi and Eli Lilly allowed her to see how having access to the care patients needed changed their lives for the better.

Phil Febbo, MD

Phil Febbo, MD, is the CMO of Illumina, and is responsible for developing and executing the company’s medical strategy to accelerate the adoption of genomic testing into health and healthcare. Dr. Febbo is a medical oncologist and physician scientist with over 100 publications who had continuous NIH funding while in academia where he held institutional and national leadership positions. He is currently an independent director for Varian and a board member for the American College of Medical Genetics and Genomics Foundation (ACMGF).

Tal Zaks, MD, PhD

Tal Zaks, M.D., Ph.D., has been partner at OrbiMed Advisors LLC since November 2021.

From 2015 to September 2021, he served as Chief Medical Officer of Moderna, Inc. From 2010 to 2015, he held senior development positions at Sanofi, including Senior Vice President and Head of Global Oncology. From 2008 to 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. From 2004 to 2008, he served as Director, Clinical Development and Translational Medicine at GlaxoSmithKline. From 1996 to 1999, he was a Postdoctoral Fellow at the National Cancer Institute.


2:00 PM
Doors Open
2:30 PM-5:45 PM
Speaker Sessions
6:00 PM
Check-in Closed
For security purposes, entrance to the IDX venue will be closed between 6:30pm sharp and 8pm. Check-in closes at 6pm.
6:00 PM
Cocktail Break
7:00 PM
Leerom Segal in Conversation with President Barack Obama
8:00 PM
Food & Entertainment
9:00 PM

Doors Open for MUSE at IDX
If you’ve already applied and been accepted to IDX 2022, you’ll have full access to MUSE that evening.

9:45 PM
Musical Performance Featuring Tiësto


How to Get There

Duggal Greenhouse at the Brooklyn Navy Yard
268, 63 Flushing Ave, Brooklyn, NY 11205, United States (map)

By ferry:
This is the easiest way to get to the venue. Ferry dock is located at Pier 16 in Manhattan. Operating hours are from 2pm – 6pm.

By rideshares or taxis:
Use "Duggal Greenhouse" as the destination. Once you're past the security gate at Brooklyn Navy Yards, look for the signs leading you to the event.

& Safety

Vaccination Requirement

All attendees will be required to be fully vaccinated against COVID-19 in order to attend, which includes all doses in the primary series, boosters are optional. Proof of vaccination will be required prior to the date of event. COVID-19 rapid test will be required upon check-in at the event.

At this time masks are optional, however all are welcome to wear a mask during the event.

Highlights from Past Events

Bringing the future
of health to life.

If you're enjoying the ideas on IDX, and are ready to spark some new ones, we want to hear from you.

Join Us

If you're enjoying the ideas on IDX, and
are ready to spark some new ones, we
want to hear from you.